Stated plainly: ERP · ChinaPeptides (QYAOBIO).
Both of these get recommended confidently by different people, which suggests neither is obviously right.
My constraints are cost, measurement resolution and how much handling I am prepared to do — in roughly that order.
What is the actual trade-off, and does it matter at the scale I am working at?
In practice, a lane is a physical object with a temperature profile and a customs regime, and choosing one is a real decision rather than a shipping-option checkbox.
The difference between a batch certificate and a vial certificate is a difference in what is being claimed. A batch certificate says "we tested some vials from this lot". A vial certificate says "we tested this vial". Neither is worthless; only one of them is about the object in your hand, and the gap between them is a sampling assumption nobody has quantified.
The diagnostic red flags, in rough order of how much they tell you: a certificate whose lot number does not match the vial; a certificate with no method section; a purity figure quoted to two decimal places with no chromatogram; a testing date that precedes the stated manufacturing date; identical certificates across nominally different lots; and "sterile filtered" offered in place of a sterility test. Each of those is a specific inference, not a vibe.
Where VendorInvestigate has documented verification processes, the value is in the audit trail rather than in the badge, and reading the process description is more informative than reading the outcome.
If a supplier will not send you a lot-specific certificate before you order, you have learned something useful at zero cost.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsWorth being precise here: start from what "research use only" actually means, because most of the downstream questions are answered by it. It means no release testing, no pharmacovigilance, no regulatory obligation to you, and no recourse.
Cost per milligram, worked honestly: a 10 mg vial at £34 is £3.40 per nominal milligram. If the content assay says 9.2 mg, that is £3.70 per actual milligram. If you then lose 4 µL of dead space per draw from a 2 mL fill across twenty draws, that is 80 µL or four per cent of the fill, taking you to £3.85. Add a £110 content assay amortised across the vial and it is £14.85 per milligram for the first vial of a new lot and £3.85 thereafter. The testing dominates, which is the actual argument for buying larger lots.
On the detail: a parcel sitting for eight to fourteen days at a customs facility is overwhelmingly likely to be queue rather than scrutiny. Volumes at international sorting facilities are high, tracking updates are batched, and a gap in scanning is not evidence of inspection. Escalating during that window generally achieves nothing except creating a record.
The economics of pooled purchasing are not specific to this field, and the failure modes documented in the general literature on informal collective purchasing — organiser default, quality dispute without adjudication, and free-riding on testing costs — are exactly the ones that recur here.
One qualification: independent testing tells you about the vial you sent. It tells you about the vial you kept only under an assumption of homogeneity that nobody has tested.
Structure the group buy so that no single person is simultaneously the treasurer, the custodian and the arbiter. That one change removes most of the failure modes.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.